Fluidigm Estimates Investment in Verinata at $3.1M After Illumina Acquisition | GenomeWeb

NEW YORK (GenomeWeb News) – Fluidigm disclosed in its Form 10-K this week that the fair value of its investment in Verinata Health is an estimated $3.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.